Bluejay Diagnostics (BJDX) Stock Price, News & Analysis

Company Overview

Bluejay Diagnostics, Inc. is a medical technology company focused on developing rapid, decentralized diagnostic solutions for use at the point of care. The company’s products are designed to help healthcare professionals obtain timely information from blood samples, supporting clinical decision-making in acute-care settings.

Bluejay’s primary technology is the Symphony System, a compact analyzer and disposable testing platform intended to measure clinically relevant biomarkers from whole blood. The system is designed to provide results near the patient rather than requiring samples to be sent to a centralized laboratory. The company has focused its development efforts on applications such as sepsis and other conditions in which rapid assessment may assist with patient management.

Bluejay Diagnostics is based in the United States and has directed its activities primarily toward the U.S. healthcare market. The company continues to develop and advance its Symphony platform and related diagnostic applications for hospitals, emergency departments, and other acute-care environments.

Key Stats

• Today's Range: $0.79 to $0.83
• 50-Day Range: $0.76 to $1.24
• 52-Week Range: $0.76 to $15.12
• Volume: 93,869 shs
• Average Volume: 2.39 million shs
• Market Capitalization: $3.68 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Bluejay Diagnostics Stock Analysis - MarketRank™

Bluejay Diagnostics scored higher than 15% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Bluejay Diagnostics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Bluejay Diagnostics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Bluejay Diagnostics is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bluejay Diagnostics is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Bluejay Diagnostics has a P/B Ratio of 0.10. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.43% of the float of Bluejay Diagnostics has been sold short.

Short Interest Ratio / Days to Cover

Bluejay Diagnostics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bluejay Diagnostics has recently increased by 9.32%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bluejay Diagnostics does not currently pay a dividend.

Dividend Growth

Bluejay Diagnostics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Bluejay Diagnostics this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for BJDX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Bluejay Diagnostics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $47,798.00 in company stock, which represents 1.2979% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Bluejay Diagnostics insiders have bought 97.72% more of their company's stock than they have sold. Specifically, they have bought $96,711.00 in company stock and sold $48,913.00 in company stock.

Percentage Held by Insiders

6.10% of the stock of Bluejay Diagnostics is held by insiders.

Percentage Held by Institutions

18.47% of the stock of Bluejay Diagnostics is held by institutions.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 10/09/2026
• Next Earnings (Estimated): 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:BJDX
• CIK: 1704287
• Web: www.bluejaydx.com
• Phone: 844-327-7078
• Fax: N/A
• Employees: 6
• Year Founded: 2015

Profitability

• EPS (Trailing Twelve Months): ($7.11)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.85 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -125.00%
• Return on Assets: -99.79%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.64
• Quick Ratio: 4.64

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.43 per share
• Price / Book: 0.10

Miscellaneous

• Outstanding Shares: 4,470,000
• Free Float: 4,195,000
• Market Cap: $3.68 million
• Optionable: Not Optionable
• Beta: 0.89